Anticoagulation

Triple Therapy in Coronary Artery Disease With GI Bleeding May Increase Mortality Risk

Triple Therapy in Coronary Artery Disease With GI Bleeding May Increase Mortality Risk

Triple therapy is associated with increased mortality risk in patients with LGIB and CAD.

Renal Function Outcomes in Atrial Fibrillation With Oral Anticoagulation Therapy

Renal Function Outcomes in Atrial Fibrillation With Oral Anticoagulation Therapy

By

Patients with atrial fibrillation who are treated with oral anticoagulants often experience renal function decline.

Warfarin Chemical Stability Not Affected by Repackaging Into Dose Administration Aids

Warfarin Chemical Stability Not Affected by Repackaging Into Dose Administration Aids

The chemical stability of warfarin sodium tablets is not affected by repackaging into dose administration aids.

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

By

A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.

ACC Expert Consensus: Management of Bleeding Associated With Oral Anticoagulants

ACC Expert Consensus: Management of Bleeding Associated With Oral Anticoagulants

By

The American College of Cardiology released an expert consensus decision pathway intended to guide clinicians in managing bleeding in patients treated with anticoagulation.

Incident Atrial Fibrillation: Direct Oral Anticoagulants vs Warfarin

Incident Atrial Fibrillation: Direct Oral Anticoagulants vs Warfarin

By

Compared with warfarin, direct oral anticoagulants lowered the risk for stroke and death risk in patients with incident atrial fibrillation.

DOACs Not Associated With Increased Bleeding Risk Compared With Warfarin

DOACs Not Associated With Increased Bleeding Risk Compared With Warfarin

Direct oral anticoagulant use is not associated with increased risk of major bleeding or mortality for patients with venous thromboembolism.

Genotype-Guided Warfarin Dosing Improves Safety After Hip or Knee Arthroplasty.

Genotype-Guided Warfarin Dosing Improves Safety After Hip or Knee Arthroplasty.

Genotype-guided warfarin dosing is associated with reduced risk of adverse events in hip or knee arthroplasty patients.

Genetic Variant Associated With Mortality in Venous Thromboembolism

Genetic Variant Associated With Mortality in Venous Thromboembolism

Venous thromboembolism events and mortality linked to genetic variant in elderly patients treated with vitamin K antagonists.

Long-Term Aspirin Unnecessary Following Atrial Fibrillation Ablation

Long-Term Aspirin Unnecessary Following Atrial Fibrillation Ablation

By

Patients with atrial fibrillation who are at a low risk for stroke do not receive a major benefit from long-term aspirin therapy.

Senior Patients With Atrial Fibrillation Not Receiving Anticoagulants

Senior Patients With Atrial Fibrillation Not Receiving Anticoagulants

Fewer than 45% of patients with atrial fibrillation aged 75 years or older receive anticoagulants upon hospital admission.

Intraocular Bleeding Risk Reduced With NOACS Compared With Warfarin

Intraocular Bleeding Risk Reduced With NOACS Compared With Warfarin

By

Novel oral anticoagulants lead to a one-fifth reduction in the risk of intraocular bleeding, compared with warfarin in patients with atrial fibrillation or venous thromboembolism.

Preventing Venous Thromboembolism After Hip, Knee Arthoplasty: Comparing Anticoagulant Efficacy

Preventing Venous Thromboembolism After Hip, Knee Arthoplasty: Comparing Anticoagulant Efficacy

By

Fondaparinux and rivaroxaban have higher efficacy of reducing venous thromboembolism after total hip or knee arthroplasty, but also an increased risk of major bleeding.

Newly Diagnosed Atrial Fibrillation Benefits From Cardiology Care vs Primary Care

Newly Diagnosed Atrial Fibrillation Benefits From Cardiology Care vs Primary Care

By

Cardiology care in patients with newly diagnosed atrial fibrillation was associated with reductions in stroke and death.

Anticoagulant Effect of Dabigatran Successfully Reversed in Emergency Situations

Anticoagulant Effect of Dabigatran Successfully Reversed in Emergency Situations

Idarucizumab can effectively reverse the anticoagulant effect of dabigatran.

Anticoagulant Recall:  Incorrect Dose Discovered in Bottle

Anticoagulant Recall: Incorrect Dose Discovered in Bottle

By

Bristol-Myers Squibb is recalling one lot of Eliquis after finding that 1 of the bottles contained the wrong dosage.

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

By

A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.

Maternal and Fetal Risk with Anticoagulation in Pregnancy

Maternal and Fetal Risk with Anticoagulation in Pregnancy

Anticoagulation treatment for patients with mechanical heart valves during pregnancy is linked to maternal and fetal risks.

New Model Predicts Gastrointestinal Bleeding in Anticoagulated Patients

New Model Predicts Gastrointestinal Bleeding in Anticoagulated Patients

A new model can help predict acute gastrointestinal bleeding, associated with increased risk of all-cause mortality.

Predicted Risk of Venous Thromboembolism May Warrant Restarting Anticoagulation

Predicted Risk of Venous Thromboembolism May Warrant Restarting Anticoagulation

Treating patients with at least a 17.5% predicted one-year venous thromboembolism risk may cost-effective.

Oral Anticoagulation Treatment Benefits From Electronic-Health-Based Management

Oral Anticoagulation Treatment Benefits From Electronic-Health-Based Management

Fewer adverse events were linked to electronic-health-based management of oral anticoagulation therapy.

Dementia Risk in Atrial Fibrillation Increases With Delayed Anticoagulation

Dementia Risk in Atrial Fibrillation Increases With Delayed Anticoagulation

By

The delayed start of anticoagulation treatment for atrial fibrillation has been linked to an increase risk for dementia.

Newly Diagnosed Atrial Fibrillation Benefits From Rivaroxaban, Dabigatran

Newly Diagnosed Atrial Fibrillation Benefits From Rivaroxaban, Dabigatran

By

Direct oral anticoagulation reduced the risk of congestive heart failure admissions and all-cause mortality in both genders.

Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&A

Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&A

By

Incidence of major bleeding events was lower with dabigatran vs warfarin in atrial fibrillation ablation.

VTE Recurrence Risk Reduced With Rivaroxaban: Q&A With EINSTEIN CHOICE Investigator

VTE Recurrence Risk Reduced With Rivaroxaban: Q&A With EINSTEIN CHOICE Investigator

By

Results from the EINSTEIN CHOICE trial plus an interview with investigator Philip Stephen Wells, MD, FRCP(C), MSc.

Anticoagulation Therapy in Patients With Atrial Fibrillation

Anticoagulation Therapy in Patients With Atrial Fibrillation

According to research, many patients with afib who were later diagnosed with acute ischemic stroke may not have been receiving appropriate anticoagulation therapy.

Intracerebral Hemorrhage: Restarting Oral Anticoagulation

Intracerebral Hemorrhage: Restarting Oral Anticoagulation

By

Regardless of intracerebral hemorrhage location, restarting oral anticoagulation is associated with favorable outcomes.

NOACS More Adopted Into Clinical Practice

NOACS More Adopted Into Clinical Practice

Of the 80% of patients prescribed oral anticoagulants, nearly 50% were prescribed non-vitamin K antagonist anticoagulants.

Periprocedural Anticoagulation in Atrial Fibrillation: American College of Cardiology Decision Pathway

Periprocedural Anticoagulation in Atrial Fibrillation: American College of Cardiology Decision Pathway

By

The American College of Cardiology released a decision pathway for managing periprocedural anticoagulation in patients with nonvalvular atrial fibrillation

Atrial Fibrillation Inpatient Costs: Dabigatran, Rivaroxaban, and Warfarin

Atrial Fibrillation Inpatient Costs: Dabigatran, Rivaroxaban, and Warfarin

Compared with warfarin, inpatient costs for newly diagnosed atrial fibrillation were lower for dabigatran and rivaroxaban.

Sign Up for Free e-Newsletters